(Q37335377)

19 August 2017

1 reference

title

Biomarkers for malignant pleural mesothelioma: current status (English)

1 reference

malignant pleural mesothelioma

19 August 2017

0 references

1 reference

Laurent Greillier

1

1 reference

19 August 2017

Paul Baas

2

1 reference

19 August 2017

John J Welch

3

1 reference

19 August 2017

Baktiar Hasan

4

1 reference

19 August 2017

Alexandre Passioukov

5

1 reference

19 August 2017

publication date

1 January 2008

1 reference

Molecular Diagnosis and Therapy

19 August 2017

published in

1 reference

19 August 2017

volume

12

1 reference

19 August 2017

issue

6

1 reference

19 August 2017

page(s)

375-390

1 reference

https://scigraph.springernature.com/pub.10.1007/bf03256303

19 August 2017

exact match

0 references

cites work

Environmental exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Malignant mesothelioma in south east England: clinicopathological experience of 272 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

The European mesothelioma epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Asbestos and mesothelioma: worldwide trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Multimodality approach in management of malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

The management of malignant pleural mesothelioma; single centre experience in 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Mesothelioma and asbestos-related pleural diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Diagnostic value of CYFRA 21-1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Diagnostic value of CA 549 in pleural fluid. Comparison with CEA, CA 15.3 and CA 72.4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Osteopontin as a potential diagnostic biomarker for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Mesothelin: a new target for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Soluble mesothelin-related protein--a blood test for mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Gene expression profiling of malignant mesothelioma cell lines: cDNA array study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Gene expression profiling identifies matriptase overexpression in malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Expression of tumor-associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

90K (Mac-2 BP) and galectins in tumor progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Serum PDGF-AB in pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Malignant pleural mesothelioma and epidermal growth factor receptor (EGF-R). Relationship of EGF-R with histology and survival using fixed paraffin embedded tissue and the F4, monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

The multiple roles of PTEN in tumor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

PTEN expression is a strong predictor of survival in mesothelioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

p53, p21 and metallothionein immunoreactivities in patients with malignant pleural mesothelioma: correlations with the epidemiological features and prognosis of mesotheliomas with environmental asbestos exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Expression of bcl-2 family members in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Over-expression of tenascin-C in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Angiogenesis is an independent prognostic factor in malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Using Gene Expression Ratios to Predict Outcome Among Patients With Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Validation of genomics-based prognostic tests in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Gene expression profiles predict survival and progression of pleural mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Gene expression profiling identifies molecular subtypes of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Mesothelin-family proteins and diagnosis of mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Combined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Soluble Mesothelin–related Peptides in the Diagnosis of Malignant Pleural Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256303

CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions

21 January 2018

1 reference

12 December 2020

Syndecan-1 expression in malignant mesothelioma: correlation with cell differentiation, WT1 expression, and clinical outcome

1 reference

12 December 2020

Circulating immunostimulatory protein 90K and soluble interleukin-2-receptor in human ovarian cancer

1 reference

12 December 2020

Trimodality management of malignant pleural mesothelioma

1 reference

12 December 2020

Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.

1 reference

12 December 2020

Gene expression correlates of clinical prostate cancer behavior

1 reference

12 December 2020

Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21-1) in the differentiation of malignant and benign pleural effusions

1 reference

12 December 2020

Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma

1 reference

12 December 2020

Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients

1 reference

12 December 2020

p27 immunostaining is related to prognosis in malignant mesothelioma

1 reference

12 December 2020

Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer

1 reference

12 December 2020

Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer.

1 reference

12 December 2020

p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma

1 reference

12 December 2020

The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma

1 reference

12 December 2020

Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies

1 reference

12 December 2020

Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil

1 reference

12 December 2020

Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma

1 reference

12 December 2020

Asbestos exposure, pleural mesothelioma, and serum osteopontin levels

1 reference

12 December 2020

Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions

1 reference

12 December 2020

Tumor Necrosis Correlates With Angiogenesis and Is a Predictor of Poor Prognosis in Malignant Mesothelioma *

1 reference

12 December 2020

Gene expression profiling of malignant mesothelioma.

1 reference

12 December 2020

Non-invasive diagnosis of pleural malignancies: the role of tumour markers

1 reference

12 December 2020

Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients

1 reference

12 December 2020

Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer

1 reference

12 December 2020

Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions

1 reference

12 December 2020

Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TGF beta expression

1 reference

12 December 2020

Expression and prognostic significance of hypoxia-inducible factor 1alpha (HIF-1alpha) in malignant pleural mesothelioma (MPM)

1 reference

12 December 2020

EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma

1 reference

12 December 2020

EGFR overexpression in malignant pleural mesothelioma

1 reference

12 December 2020

Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray.

1 reference

12 December 2020

Prognostic significance of Bax and Fas ligand in erionite and asbestos induced Turkish malignant pleural mesothelioma

1 reference

12 December 2020

Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma

1 reference

12 December 2020

Diagnostic utility of CYFRA 21-1 in malignant pleural effusion

1 reference

12 December 2020

Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial.

1 reference

12 December 2020

Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma

1 reference

12 December 2020

Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma

1 reference

12 December 2020

The relationship between aberrant methylation and survival in non-small-cell lung cancers

1 reference

12 December 2020

Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma.

1 reference

12 December 2020

Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.

1 reference

12 December 2020

High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis

1 reference

12 December 2020

P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma

1 reference

12 December 2020

Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level determinations in the serum and pleural fluid of patients with pleural effusions

1 reference

12 December 2020

Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma.

1 reference

12 December 2020

Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma

1 reference

12 December 2020

The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050.

1 reference

12 December 2020

Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma

1 reference

12 December 2020

Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma

1 reference

12 December 2020

Thymidylate synthase predicts for clinical outcome in invasive breast cancer

1 reference

12 December 2020

Meta-analysis of several gene lists for distinct types of cancer: a simple way to reveal common prognostic markers

1 reference

12 December 2020

Prognostic significance of flow cytometric DNA analysis in patients with malignant pleural mesothelioma

1 reference

12 December 2020

Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma

1 reference

12 December 2020

Expression of glycoprotein 90K in human malignant pleural mesothelioma: correlation with patient survival.

1 reference

12 December 2020

Prognostic significance of presence and reduplication of basal lamina in malignant pleural mesothelioma

1 reference

12 December 2020

Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients

1 reference

12 December 2020

Differential gene expression in mesothelioma

1 reference

12 December 2020

Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma

1 reference

12 December 2020

Evaluation of cytokeratin 19 fragment (CYFRA 21-1) as a tumor marker in malignant pleural effusion

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03256303

1 reference

19 August 2017

1 reference